Company Encyclopedia
View More
name
GUANGYUYUAN
600771.SH
GuangYuYuan Chinese Herbal Medicine Co., Ltd. manufactures and sells Chinese medicinal products. The company offers traditional Chinese medicine, fine Chinese medicine, and health wine. It provides its products in the form of pills, powders, tablets, hard capsules, granules, mixtures, and wine preparations.
3.144 T
600771.SHMarket value -Rank by Market Cap -/-

Financial Score

10/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking36/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.12%C
    • Profit Margin5.93%B
    • Gross Margin66.85%A
  • Growth ScoreB
    • Revenue YoY15.04%B
    • Net Profit YoY18.54%B
    • Total Assets YoY2.40%C
    • Net Assets YoY5.26%B
  • Cash ScoreB
    • Cash Flow Margin1685.78%B
    • OCF YoY15.04%B
  • Operating ScoreB
    • Turnover0.57B
  • Debt ScoreB
    • Gearing Ratio32.06%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chengxin Lithium Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Chengxin Lithium Group Co., Ltd. reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 3,094.61 million compared to CNY 3,498.04 million a year ago. Net loss was CNY 752.33 million compared to CNY 461.65 million a year ago.Basic loss per share from continuing operations was CNY 0.83 compared to CNY 0.51 a year ago. Diluted loss per share from continuing operations was CNY 0.83 compared to CNY 0.51 a year ago.

    marketscreener·
    SZ
    002240
    +5.97%
    marketscreener·
    SZ
    002240
    +5.97%

    GUANGYUYUAN released its performance for the first half of the year, with a net profit attributable to the parent company of 76.8571 million yuan, an increase of 28.95%

    According to the Zhitong Finance APP, GUANGYUYUAN released its semi-annual report for 2025, showing an operating income of 779 million yuan, a year-on-year increase of 18.14%. The net profit attributable to shareholders of the listed company was 76.8571 million yuan, a year-on-year increase of 28.95%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 67.9986 million yuan, a year-on-year increase of 21.76%. The basic earnings per share were 0.16 yuan

    Zhitong·
    SH
    600771
    -0.38%
    Zhitong·
    SH
    600771
    -0.38%

    GUANGYUYUAN: The holding subsidiary received a government subsidy of 7.5521 million yuan

    GUANGYUYUAN announced in the evening that on June 27, its holding subsidiary Tibet GUANGYUYUAN Pharmaceutical Co., Ltd. received a government subsidy related to revenue of 7.5521 million yuan, accounting for 10.14% of the company's net profit for the 2024 fiscal year

    Zhitong·
    SH
    600771
    -0.38%
    Zhitong·
    SH
    600771
    -0.38%

    GUANGYUYUAN released its first-quarter performance, with a net profit attributable to the parent company of 63.58 million yuan, a year-on-year increase of 53.94%

    According to the Zhitong Finance APP, GUANGYUYUAN disclosed its first-quarter report for 2025, showing that the company achieved revenue of 417 million yuan during the reporting period, a year-on-year increase of 21.48%; net profit attributable to shareholders was 63.58 million yuan, a year-on-year increase of 53.94%; and net profit excluding non-recurring gains and losses was 63.64 million yuan, a year-on-year increase of 31.24%. The basic earnings per share were 0.1299 yuan

    Zhitong·
    SH
    600771
    -0.38%
    Zhitong·
    SH
    600771
    -0.38%

    GUANGYUYUAN: The reshaping of turtle wine is one of the company's product strategies, and this work has always been carried out around the company's resource advantages

    GUANGYUYUAN stated on the interactive platform that the reshaping of turtle wine is one of its product strategies, deployed around resource advantages. The company holds various licenses and qualifications for alcoholic products, and the establishment of the liquor company aims to enhance product quality and standardize technical standards. Medicinal wine and health wine are the main products, and the company will focus on core operational measures, with resource investment and output assessment also concentrated on core products

    Zhitong·
    SH
    600771
    -0.38%
    Zhitong·
    SH
    600771
    -0.38%
    © 2025 Longbridge｜Disclaimer